When a journal like Science dedicates a special section to one class of drugs, it is a sign that a field has arrived. The November 5, 2026, package, titled “Going Beyond GLP-1,” marks that arrival. But read its six expert contributions together and a less comfortable message emerges: on several questions patients, clinicians and investors care about most, including GLP-1 cancer risk, thinking and memory, and whether these drugs can help treat addiction, the evidence remains unsettled.
The package contains three Reviews, two Perspectives and one Policy Forum. It does not report a new randomized clinical trial. Instead, it takes stock of a field that has moved beyond asking whether GLP-1-based medicines reduce body weight and blood glucose toward asking what else they might accomplish, how those effects work and who can access them.
That distinction matters. Evidence for approved metabolic uses is one thing. Claims that the same medicines prevent cancer, improve cognition or treat substance-use disorders require their own clinical evidence.
And the scientists writing in Science are not ready to close those files.
The GLP-1 Cancer Risk Question Is Still Open
The most pointed contribution may be a Perspective by Blánaid Hicks of Queen’s University Belfast and Anton Pottegård of the University of Southern Denmark, two researchers working in pharmacoepidemiology: the study of medicines and their effects across populations.
Their Perspective, “GLP-1 therapies and cancer risk,” stresses the importance of interpreting evidence correctly in a rapidly changing medical field.
According to the American Association for the Advancement of Science (AAAS), the authors argue that stronger evidence combining clinical trials, observational studies and laboratory research is needed to establish whether GLP-1-based therapies meaningfully affect cancer risk.
That is an important corrective to the expanding stream of medical-record studies associating GLP-1 treatment with higher or lower rates of particular cancers.
Observational data can generate valuable signals, especially when randomized trials are not large enough or long enough to measure uncommon outcomes. But observational comparisons can also be distorted by differences between people who receive a drug and those who do not.
Patients prescribed newer medicines may differ in weight, diabetes severity, access to care, cancer-screening history and other risk factors. Some may receive more medical attention, increasing the likelihood that an existing cancer is detected. Others may lose substantial weight, independently changing their long-term risk of obesity-related disease.
Those differences make it difficult to isolate whether a drug itself changes cancer risk, whether weight loss explains the association or whether the apparent signal comes from study design.
This uncertainty should not be confused with proof that GLP-1 medicines cause cancer. Nor is it proof that they prevent it. Existing product-specific warnings, including those arising from thyroid C-cell tumor findings in rodents, are a separate regulatory issue from claims about broad cancer prevention or cancer incidence in humans.
A cancer association in health records is not automatically a drug effect. The methods used to produce the association matter.
Pottegård’s comments to AAAS also emphasize transparency and reproducibility in real-world evidence. That is the methodological work required before potentially important signals can become reliable conclusions.
Brains, Memory and the Trouble With Mixed Results
A Review by Stina Börchers, Giulia Mazzini, Henrik Zetterberg and Christoffer Clemmensen examines obesity medications and cognition.
Its abstract explicitly describes the findings across preclinical experiments, observational cohorts and clinical trials as mixed.
One central difficulty is separating potential direct effects on brain circuits from the indirect consequences of improved metabolic and cardiovascular health.
That distinction is critical. Better glucose control, reduced vascular risk and substantial weight loss may influence brain health without proving that a GLP-1 medicine directly protects neurons from degeneration.
Likewise, an observational association with reduced dementia diagnoses is not equivalent to a randomized trial showing that a drug slows Alzheimer’s disease after symptoms have developed.
The Review examines the evidence across cardiometabolic disease, aging and Alzheimer’s disease, extending beyond GLP-1 alone to approaches involving GIP, glucagon and amylin pathways.
The authors highlight several biological questions that may shape outcomes: the pharmacology of each receptor, how much medicine reaches relevant brain regions, the patient’s metabolic condition and the stage of neurological disease.
Those are not minor technicalities. A drug that changes brain activity in an animal experiment may not deliver the same exposure or clinical effect in a person living with a complex neurological disorder.
In the AAAS release, Clemmensen calls for rigorous trial designs, appropriate controls and careful interpretation of observational findings.
For readers following the GLP-1 and Alzheimer’s story, the practical message is to separate three questions: whether the medicines influence brain biology, whether they improve measurable cognition, and whether they prevent or treat clinical dementia.
They are related questions, but they do not have identical answers.
Addiction: A Reward-System Story, and Maybe More
The second Perspective comes from Nora Volkow, director of the U.S. National Institute on Drug Abuse, and her NIDA colleague Eric Wargo.
Their article considers whether GLP-1-based therapies might become useful tools in addiction treatment and broader approaches to health care.
Research has raised the possibility that medicines developed for metabolic conditions may influence craving, reward and consumption of alcohol or other substances.
Some investigators have focused on dopamine-related reward circuits, but Volkow and Wargo argue that the explanation may reach further into metabolic, hormonal, inflammatory and cardiovascular biology.
That broader framing matters because addiction is not solely a malfunction of one brain pathway. It is shaped by interactions among biological vulnerability, behavior, environmental conditions and health.
It also changes how researchers might design future trials. A reduction in reported craving, a decrease in alcohol consumed and sustained recovery from alcohol-use disorder are not interchangeable outcomes.
Early clinical and observational findings can justify more research without establishing an approved treatment.
The participation of NIDA’s director in a Science Perspective underscores the seriousness of the research question. It is not evidence that GLP-1 medicines are already proven addiction therapies.
The research has moved beyond whether GLP-1 drugs influence the brain. The harder question is whether those effects translate into durable clinical benefits.
Beyond the Scale: Fat Tissue Is More Than Stored Energy
Two Reviews broaden the discussion beyond cancer, cognition and addiction.
In “When fat adapts: From physiological remodeling to disease,” Karima Drareni and Patrick Seale explain how adipose tissue changes in response to the demands placed on the body.
That remodeling involves more than fat cells becoming larger or smaller. It includes changes in cellular populations, extracellular support structures, blood supply, immune composition and nerve connections.
Healthy remodeling allows fat tissue to store and release energy and communicate with other organs. Disrupted remodeling can contribute to metabolic disease and local tissue dysfunction.
The authors also examine how fat surrounding tumors can form a metabolic and inflammatory environment that supports cancer progression.
Weight loss may reverse many harmful changes in adipose tissue, but some alterations can persist.
That leaves researchers with a more difficult therapeutic ambition: not simply reducing fat mass, but restoring healthier tissue function.
The distinction could eventually matter for how metabolic therapies are evaluated. A smaller amount of adipose tissue is not automatically the same as tissue with normal immune, vascular and metabolic behavior.
The Review provides a biological framework for future treatments, not evidence that a particular GLP-1 drug can fully reverse pathological fat-tissue remodeling.
The Next Obesity Drugs Have More Problems to Solve
Matthias Blüher’s Review, “Obesity management medications: The way forward,” examines both the transformation of obesity pharmacology and the limitations of its current treatments.
Modern medicines can produce substantial, sustained weight loss in clinical trials. But patients vary in their responses, gastrointestinal side effects can limit treatment, adherence is imperfect and weight regain remains a concern when therapy stops.
Significant weight loss can also involve reductions in lean mass, although lean mass and functional skeletal muscle are not the same measurement.
The next generation of obesity treatments is being designed around those remaining problems.
Prominent research strategies include triple-receptor agonists, medicines targeting amylin pathways, oral formulations and combinations intended to preserve muscle during substantial weight reduction.
That evolving drug-development strategy is visible in our analysis of retatrutide’s three-receptor mechanism, where GLP-1, GIP and glucagon signaling are combined in one investigational molecule.
It is also visible in our reporting on trevogrumab and the muscle-preservation market, where developers are investigating whether an additional medicine can change the composition of drug-induced weight loss.
Neither strategy guarantees a better overall therapy. Adding biological mechanisms can introduce new questions about tolerability, safety, manufacturing and cost.
As obesity treatment matures, the important questions are expanding beyond the largest percentage on a weight-loss chart.
The next competition will also concern durability, tolerability, muscle function, access and long-term metabolic health.
Access Is Part of the Science, Not an Afterthought
The Policy Forum by Kenneth Shadlen and Olivier Wouters brings the special section back to a problem that no receptor diagram can solve: who can actually obtain these medicines?
In “Expanding global access to GLP-1s: Challenges and opportunities,” they examine the uneven availability of newer metabolic treatments around the world.
Access has been concentrated in wealthier countries even as many low- and middle-income countries face substantial burdens from obesity and diabetes.
Affordable prices, generic competition and licensing arrangements can help widen availability, but the authors emphasize that those changes alone are insufficient.
Health systems must also have the resources to purchase medicines, distribute them reliably and support patients who need ongoing treatment.
The wider economic, dietary and environmental drivers of metabolic disease cannot be addressed through pharmaceutical supply alone.
That makes access part of the real-world effectiveness question. A medicine may perform exceptionally well in a trial while remaining unavailable to large numbers of people who could benefit from it.
Read together, the six contributions are less a victory lap than an assessment of unfinished work.
GLP-1-based drugs have established clinical benefits in weight management and glucose control, alongside important evidence in other approved indications. That success has opened new questions about cancer, cognition, addiction, fat-tissue biology, treatment design and global access.
The questions do not all have the same evidence base. Some have promising mechanistic findings, some have observational signals and some are being tested in clinical trials. None should be declared settled merely because an association makes a compelling headline.
The most useful message from Science is not that GLP-1 drugs will treat everything. It is that understanding what they can do beyond their established uses requires better evidence than excitement alone.
Sources
AAAS: Special Issue: Targeting metabolism and GLP-1-based drugs. November 5, 2026. Publisher’s overview of the six-paper package.
Cancer risk: Hicks B, Pottegård A. GLP-1 therapies and cancer risk. Science. November 5, 2026. DOI: 10.1126/science.aei1490.
Cognition: Börchers S, Mazzini G, Zetterberg H, Clemmensen C. Obesity pharmacotherapies and cognition. Science. November 5, 2026. DOI: 10.1126/science.aek9987.
Addiction: Volkow ND, Wargo EM. GLP-1 receptor agonists in addiction therapy. Science. November 5, 2026. DOI: 10.1126/science.aej9836.
Adipose biology: Drareni K, Seale P. When fat adapts: From physiological remodeling to disease. Science. November 5, 2026. DOI: 10.1126/science.aee9044.
Next-generation obesity treatments: Blüher M. Obesity management medications: The way forward. Science. November 5, 2026. DOI: 10.1126/science.aej1120.
Global access: Shadlen KC, Wouters OJ. Expanding global access to GLP-1s: Challenges and opportunities. Science. November 5, 2026. DOI: 10.1126/science.aek2174.
